James L. Gulley, MD, PhD
An investigational prostate cancer vaccine has shown potential to improve survival in patients with metastatic castration-resistant prostate cancer (CRPC), according to the results of early clinical evaluations.
In a phase II, randomized, double-blind, placebo-controlled trial, 125 patients with minimally symptomatic metastatic CRPC were randomized 2:1 to PROSTVAC-VF or to control empty vectors (
. 2010;28:1099-1105). Patients randomized to the immunotherapy received a priming dose of PROSTVAC-V, followed by six booster doses of PROSTVAC-F given with low-dose granulocyte- macrophage colony-stimulating factor (GM-CSF).
How pox viral vaccines activate tumor-associated antigen specific T- cells.